» Articles » PMID: 20139821

Comparative Evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for Metabolic Imaging of Low Grade Gliomas

Overview
Journal Clin Nucl Med
Specialty Nuclear Medicine
Date 2010 Feb 9
PMID 20139821
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: We undertook this prospective study to compare amino acid metabolism, glucose metabolism, and proliferation in primary and recurrent low grade gliomas using positron emission tomography (PET)/computed tomography with F-18 FDOPA, F-18 FDG, and F-18 FLT.

Methods: Fifteen patients with newly diagnosed or previously treated low grade gliomas (WHO grade I or II) were subjected to F-18-FDOPA, F-18 FDG, and F-18 FLT PET/computed tomography studies on consecutive days. This included 2 patients in remission as control subjects. Uptake of all the 3 tracers were analyzed visually and quantified using standardized uptake values and tumor to normal (T/N) ratios. The accuracy of all the 3 PET tracers in the detection of newly diagnosed and recurrent low grade gliomas was compared.

Results: F-18 FDOPA was positive in all cases of primary and recurrent low grade gliomas and negative in the patients in remission. Tumor was visualized on F-18 FDG in 7 of 13 cases, F-18-FLT was positive in 4 of 13 cases. Average tumor standardized uptake values max for F-18 FDOPA (5.75 +/- 4.9) and F-18 FLT (1.8 +/- 0.91) was lower than that of F-18 FDG (8.5 +/- 4.4). T/N ratios for F-18-FDOPA (2.3 +/- 0.51) and F-18 FLT (1.8 +/- 0.91) were higher than F-18 FDG (1.03 +/- 0.64) providing good image contrast for tumor detection in positive cases.

Conclusion: F-18 FDOPA scan is superior to both F-18 FLT and F-18 FDG for visualization of primary and recurrent low grade gliomas. F-18-FLT should not be considered for evaluation of recurrent low grade gliomas.

Citing Articles

Recent Update on PET/CT Radiotracers for Imaging Cerebral Glioma.

Kim D, Lee S, Hwang H, Kim S, Yun M Nucl Med Mol Imaging. 2024; 58(4):237-245.

PMID: 38932755 PMC: 11196511. DOI: 10.1007/s13139-024-00847-4.


Diagnostic accuracy of anti-3-[F]-FACBC PET/MRI in gliomas.

Karlberg A, Pedersen L, Vindstad B, Skjulsvik A, Johansen H, Solheim O Eur J Nucl Med Mol Imaging. 2023; 51(2):496-509.

PMID: 37776502 PMC: 10774221. DOI: 10.1007/s00259-023-06437-4.


Positron Emission Tomography (PET)/Computed Tomography (CT) Imaging in Radiation Therapy Treatment Planning: A Review of PET Imaging Tracers and Methods to Incorporate PET/CT.

Trotter J, Pantel A, Teo B, Escorcia F, Li T, Pryma D Adv Radiat Oncol. 2023; 8(5):101212.

PMID: 37197709 PMC: 10184051. DOI: 10.1016/j.adro.2023.101212.


Diagnostic value of PET with different radiotracers and MRI for recurrent glioma: a Bayesian network meta-analysis.

Xiaoxue T, Yinzhong W, Meng Q, Lu X, Lei J BMJ Open. 2023; 13(3):e062555.

PMID: 36863738 PMC: 9990663. DOI: 10.1136/bmjopen-2022-062555.


Differentiating high-grade glioma progression from treatment-related changes with dynamic [F]FDOPA PET: a multicentric study.

Rozenblum L, Zaragori T, Tran S, Morales-Martinez A, Taillandier L, Blonski M Eur Radiol. 2022; 33(4):2548-2560.

PMID: 36367578 DOI: 10.1007/s00330-022-09221-4.